Olanzapine intranasal (Neurelis)

奥氮平鼻喷制剂 (Neurelis)

Report date: 2024/03/14 17:57:27

Base Information

Drug NameOlanzapine intranasal (Neurelis)

Drug Alias NameNRL-4NRL-1004

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionDopamine D1 receptor antagonistsDopamine D2 receptor antagonistsSerotonin 2 (5-HT2) receptor antagonists

TargetsDopamine D1 receptorDopamine D2 receptorSerotonin 2 (5-HT2) receptor

Therapy Area/IndicationsBipolar Disorder

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNeurelis Inc

China Registration ClassN/A

Active CompaniesNeurelis Inc

Inactive CompaniesN/A

Active IndicationsBipolar Disorder

Inactive IndicationsN/A

ATC CodeN/A